Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VaxRex (HA + M1)
- Development stage
- Unknown
- Lead developer
- Metaclipse Therapeutics
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VaxRex (HA + M1) is a virus-like particle (VLP) vaccine candidate developed by Metaclipse Biopharma for the prevention of influenza, specifically targeting the elderly population (65+). Utilizing the proprietary VaxRex™ platform, the vaccine incorporates influenza hemagglutinin (HA) and matrix protein 1 (M1) antigens along with biological adjuvants. This design aims to elicit robust humoral and cellular immune responses, addressing the reduced vaccine efficacy often seen in older adults due to immunosenescence. The program is currently in early clinical development.
- Brand names
- VaxRex
- Other names
- VaxRex InfluenzaVaxRex (HA & M1 proteins)
02
Targets
M1 (Muscarinic acetylcholine receptor M1)HA (Hemagglutinin)
Beyond the preview
Go deeper on VaxRex (HA + M1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VaxRex (HA + M1).